Zentalis Pharmaceuticals' (ZNTL) "Sell (E+)" Rating Reiterated at Weiss Ratings

Key Points

• Zentalis Pharmaceuticals has had its "sell (E+)" rating reiterated by Weiss Ratings, highlighting concerns over the stock's performance.
• Wall Street analysts have varying opinions on the stock, with one "Strong Buy," one "Buy," three "Hold," and one "Sell" rating issued.
• The stock recently traded at $1.66, significantly lower than its 12-month high of $4.44, indicating volatility in its performance.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)'s stock had its "sell (e+)" rating reissued by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. Wells Fargo & Company cut their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Finally, HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $5.84.

Zentalis Pharmaceuticals Price Performance

ZNTL stock traded up $0.11 during trading hours on Wednesday, reaching $1.66. 213,447 shares of the stock were exchanged, compared to its average volume of 1,139,742. The firm's 50-day moving average is $1.57 and its 200-day moving average is $1.43. The company has a market cap of $119.68 million, a price-to-earnings ratio of -0.74 and a beta of 1.77. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.19. As a group, equities research analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth $31,000. Cerity Partners LLC grew its stake in shares of Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock worth $33,000 after buying an additional 7,579 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth $37,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth $38,000. Finally, Corient Private Wealth LLC bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth $41,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.